IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia

Inclusion Criteria

• •1.Male or female patients aged ≥18 years;
• •2.Diagnosis of eosinophilic leukemia (EL) established according to the WHO 2022 diagnostic criteria;
• •3.Interleukin-5 receptor α (IL-5Rα, CD125) is expressed on ≥50% of leukemic blasts.
• •4.Meet any of the following criteria for refractory/relapsed eosinophilic leukemia:
• •a) Inadequate response to standard therapy: failure to achieve complete remission (CR) after standard treatments (e.g., imatinib, corticosteroids, interferon-α, chemotherapy, etc.);
• •b) Disease progression/relapse within 6 months after achieving remission;
• •5.Serum total bilirubin ≤1.5 × the upper limit of normal (ULN), and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 × ULN;
• •6.Left ventricular ejection fraction (LVEF) \>50% as assessed by echocardiography;
• •7.Peripheral oxygen saturation (SpO₂) ≥92% on room air (without supplemental oxygen);
• •8.Estimated life expectancy \>3 months;
• •9.Eastern Cooperative Oncology Group (ECOG) performance status 0-1;
• •10.Women and men of childbearing potential must agree to use appropriate, effective contraception prior to study entry, throughout the study period, and for 6 months after cell infusion (the safety of this therapy for unborn children is unknown and may pose potential risks);
• •11.Patients who are willing to participate in this study and who are able to understand and voluntarily sign the written informed consent form.